NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO RECEIVES FAVOURABLE JUDGEMENT, FMC APPEAL DISMISSED05-12-2022
05-12-2022
Buy Natco Pharma; target of Rs 704: Geojit
Geojit is bullish on Natco Pharma has recommended buy rating on the stock with a target price of Rs 704 in its research report dated December 05, 2022.05-12-2022
NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for V C Nannapaneni05-12-2022
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
issue of duplicate share certificates03-12-2022
NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Natsoft Information Systems Pvt Ltd02-12-2022
NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for V C Nannapaneni01-12-2022
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificates23-11-2022
NATCO PHARMA LTD. - 524816 - Related Party Transactions For The Half Year Ended 30Th September, 2022
Related Party Transactions for the half year ended 30th September, 202222-11-2022
Hold Natco Pharma; target of Rs 660: ICICI Direct
ICICI Direct recommended hold rating on Natco Pharma with a target price of Rs 660 in its research report dated November 17, 2022.18-11-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of earnings conference call held on 11th November, 202217-11-2022